Abivax to be Added to Nasdaq Biotechnology Index
تحليل معلومات السوق
مدعوم بالذكاء الاصطناعيAbivax SA, a clinical-stage biotechnology company, will be added to the Nasdaq Biotechnology Index, indicating increased recognition and market presence.
Market impact analysis based on bullish sentiment with 75% confidence.
سياق المقال
Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective pr
التحليل والرؤى المقدمة من AnalystMarkets AI.